Related Experiment Video
Updated: Jan 30, 2026
05:47
Modified Technique for Coronary Artery Ligation in Mice
Published on: March 29, 2013
26.6K
PCSK9 Inhibitor causes a decrease in the level of oxidatively modified low-density lipoproteins in patients with
V Z Lankin1, A K Tikhaze1, M Viigimaa2
1FSBI "National Medical Research Cardiology Center" of the Ministry of Health of the Russian Federation, Moscow, Russia.
Terapevticheskii Arkhiv
|February 1, 2019
Summary
Evolocumab, a PCSK9 inhibitor, effectively lowers LDL cholesterol and reduces oxidized LDL (ox-LDL) levels in patients with coronary artery disease. Unlike statins, it does not impact antioxidant enzyme activity, suggesting no effect on oxidative stress parameters.
Area of Science:
- Cardiovascular Medicine
- Biochemistry
- Pharmacology
Background:
- Coronary artery disease (CAD) is associated with elevated levels of oxidatively modified low-density lipoprotein (ox-LDL).
- Antioxidant enzymes play a crucial role in mitigating oxidative stress.
- PCSK9 inhibitors represent a novel class of lipid-lowering therapies.
Purpose of the Study:
- To investigate the effect of the PCSK9 inhibitor evolocumab on ox-LDL levels and antioxidant enzyme activity in patients with CAD.
- To compare the impact of evolocumab with statin therapy on oxidative stress markers.
Main Methods:
- A study involving 9 male patients with CAD receiving standard therapy and maximal statin doses.
- Addition of evolocumab (420 mg monthly) for patients not achieving target LDL cholesterol levels.
- Measurement of lipid metabolism indices, plasma ox-LDL, and erythrocyte antioxidant enzyme activities (glutathione peroxidase, superoxide dismutase, catalase).
Main Results:
- Evolocumab significantly reduced plasma ox-LDL content.
- Unlike statins, evolocumab did not decrease the activity of key antioxidant enzymes.
- The PCSK9 inhibitor demonstrated effectiveness in lowering LDL cholesterol.
Conclusions:
- PCSK9 inhibition effectively reduces ox-LDL levels in CAD patients.
- Evolocumab does not negatively affect antioxidant enzyme activity.
- PCSK9 inhibitors appear to have a neutral impact on the parameters of oxidative stress.
Related Concept Videos
01:30Coronary Artery Disease I: Introduction
1.1K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.1K
01:26Coronary Artery Disease II: Pathophysiology
426
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
426
01:27Coronary Artery Disease V: Interprofessional Care
267
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
267
01:30Coronary Artery Disease III: Clinical Manifestations
368
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
368
01:26Coronary Artery Disease IV: Preventive Measures
684
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
684
01:27Decreasing Function
273
A decreasing function describes a relationship where the output consistently declines as the input increases. This means that for any two input values, if one is greater than the other, the corresponding output is smaller. Mathematically, a function f is decreasing on an interval I if for every x1 < x2 in I, f (x1) > f (x2). This type of behavior is visually identified on a graph that slopes downward from left to right.The nature of a function can be analyzed by calculating...
273